VivoSeq
Immunology

Non-Allergic Rhinitis

9

Pipeline Programs↗

1

Active Trials↗

6

Companies Involved↗

Non-Allergic Rhinitis is an early-stage landscape with 9 programs across 6 companies. The most active players are GSK, Averitas Pharma, Inc., Bayer. 3 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

35/100

Pipeline Velocity

6/100

Mech. Concentration

20/100

Completion Rate

75/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

1 program

Phase 2A

Averitas Pharma, Inc.

1 program

ApprovedBayer logo

Bayer

1 program

ApprovedM

Milestone Pharmaceuticals Inc.

1 program

ApprovedD

Dexcel Pharma Technologies Ltd.

1 program

PreclinicalC

Chengdu Kangnuoxing Biopharma,Inc.

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

6

clinical trials

Completed3 · 50%
Unknown status1 · 17%
Not yet recruiting1 · 17%
Terminated1 · 17%

Clinical Trials

Trial Activity

6 trials

Efficacy and Safety of Stapokibart in Non-Allergic Rhinitis With Eosinophilia Syndrome
Not yet recruiting·HHuazhong University of Science and Technology·N/A·NCT07240376·90 enrolled
Efficacy of Esomeprazole for Non-Allergic Rhinitis: A Double-blind, Placebo Controlled Trial
Completed·UUniversity of Texas Southwestern Medical Center·N/A·NCT00745849·43 enrolled
Intranasal SB-705498 in Non-allergic Rhinitis Patients
Completed·GSK logoGSK·Phase 2·NCT01439308·40 enrolled
The Prevalence of Local Immunoglobulin E (IgE) Elevation and Its Effect on Intranasal Capsaicin Therapy in the Non-allergic Rhinitis Population
Completed·TThe University of Texas Health Science Center, Houston·Phase 3·NCT05093478·28 enrolled
Oxymetazoline Hydrochloride in Combination With Nasal Glucocorticosteroid for Perennial Allergic and Non-allergic Rhinitis in Subjects With Persistent Nasal Congestion
Terminated·UUniversity of South Florida·N/A·NCT00584662·42 enrolled
Singulair Use in Non-Allergic Rhinitis Eosinophil Syndrome (NARES)
Unknown status·—·Phase 4·NCT00406094·6 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)